Institutional Review Board (IRB)

Protecting Trial Participants

LifeBridge Health (LBH) Institutional Review Board (IRB) is responsible for protecting the rights and welfare of human participants in research conducted by faculty, staff and residents affiliated with LifeBridge Health, Inc.

Doctor speaking with a patient

More About the IRB

The IRB ensures the protections of the rights and welfare of human research subjects based on the rules and regulations of the Department of Health and Human Services (specifically Office for Human Research Protections) and the Food and Druga Administration (FDA) by approving, requiring modifications in, or disapproving Human Subject Research projects.


LifeBridge Health has one active IRB composed of members from various disciplines in the medical, social, and behavioral sciences, as well as community members. Within LifeBridge Health, an IRB must review all research involving human participants, and the research cannot begin until the IRB has reached a determination; even if the researcher perceives there are no risks for participants.


LifeBridge Health conducts human subject research under its Federalwide Assurance (FWA) issued by the Office of Human Research Protections (OHRP). The LBH IRB complies with the registration requirements for both OHRP and the FDA. For those interested in viewing the registration, LBH’s IRB registration number is IRB00002996 and its FWA number is FWA00003667.

The IRB Roster

LifeBridge Health IRB members are selected for their willingness to serve, expertise and familiarity with research design and procedures. IRB members include faculty from a wide variety of clinical disciplines and specialties to ensure adequate expertise, legal advisors, pharmacists, nurses, bioethicists, and others to provide needed expertise. Community members and non-scientists also contribute as voting members of the LBH IRB in order to reflect the viewpoint of the general community and lay audience.


The LifeBridge Health IRB aims to maintain a diverse roster in order to review the wide variety of research conducted within LifeBridge Health. The membership of LBH IRB complies with all federal regulatory requirements.


Jason Fixler, MD


Director of Pediatric Research Sinai Hospital Sinai Hospital of Baltimore Board Certified – Pediatrics Board Certified – Pediatric Hematology/Oncology

Learn More about Jason Fixler, MD

Scientific Members

Jenna Brager, PhD, RN, MS

Executive VP, Drug Development, MyMD Pharmaceuticals Former Director of Clinical Research and Scientific Grants for LBH

Lauren Covington, PhD, RN

Pediatric Intensive Care Unit Sinai Hospital of Baltimore

Olivia Gallagher

Non-Affiliated QC Scientist II

Martin Taylor, PharmD

Pharmacy Sinai Hospital of Baltimore

Philip Young, PharmD

Inpatient Pharmacy Sinai Hospital of Baltimore

Non-Scientific Members

Paul Cummins, PhD

Non-affiliated Specialty in Bioethics

Polly Senker, MEd

Former Member Sinai Hospital, Board of Directors Past President, Sinai Hospital Auxiliary

Joel Simon, JD

Director of Corporate Development Sinai Hospital of Baltimore

Irelie Riggle, MS

Department of Research Sinai Hospital of Baltimore

Contacting the LifeBridge Health IRB

The LifeBridge Health IRB is available for questions, complaints, and general inquiries via email. Individuals are welcome to contact the IRB if their questions, concerns, or complaints are not being sufficiently answered by a research team, unable to reach the research team, would prefer to talk to someone besides the research team, have questions about their rights as a research participant, or want to obtain or provide their input about a research study in which they are participating in. Please contact us at lbhresearch@lifebridgehealth.org.

IRB Meeting Calendar & Submission Deadlines

The LBH IRB meets the fourth Wednesday of each month, from 8:15 am to 10:15 am, unless otherwise notified. Any submissions requiring full board approval must be complete and ready for convened review at least 2-weeks prior to the next IRB Meeting.

2024 IRB Meeting Dates

Submission Deadline Meeting Date
January 10, 2024 January 24, 2024
February 14, 2024 February 28, 2024
March 13, 2024 March 27, 2024
April 10, 2024 April 24, 2024
May 8, 2024 May 22, 2024
June 5, 2024 June 19, 2024
July 10, 2024 July 24, 2024
August 7, 2024 August 28, 2024
September 11, 2024 September 25, 2024
October 9, 2024 October 23, 2024
November 6, 2024 November 20, 2024
December 11, 2024 December 18, 2024